Familial breast cancer: an investigation into the outcome of treatment for early stage disease

[1]  A. Vincent-Salomon,et al.  Familial invasive breast cancers: worse outcome related to BRCA1 mutations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Bégin,et al.  Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P Borgen,et al.  Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. , 1999, Journal of the National Cancer Institute.

[4]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[5]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Skolnick,et al.  BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[8]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[9]  P. Hartge,et al.  Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[10]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[11]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[12]  J. Peto,et al.  Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. , 1998, European journal of cancer.

[13]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[14]  D. W. Abbott,et al.  Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. , 1998, Journal of the National Cancer Institute.

[15]  I. Campbell,et al.  BRCA1 mutations in southern England. , 1998, British Journal of Cancer.

[16]  J. Manola,et al.  Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Powles,et al.  Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers , 1998, The Lancet.

[18]  J. Garber.  Inherited breast cancer: increasingly familiar territory. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[22]  L. Bégin,et al.  Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M N Pollak,et al.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.

[24]  P. Tonin,et al.  Brca2 hereditary breast cancer pathophenotype , 1997, Breast Cancer Research and Treatment.

[25]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[26]  Å. Borg,et al.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. , 1997, American journal of human genetics.

[27]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[28]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[29]  P. Hasty,et al.  A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53 , 1996, Molecular and cellular biology.

[30]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[31]  I. Gage,et al.  Long-term outcome following breast-conserving surgery and radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[32]  U. Chetty,et al.  Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21 , 1994, The British journal of surgery.

[33]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[34]  J. Vilcoq,et al.  Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. , 1989, International journal of radiation oncology, biology, physics.

[35]  J. Jacquemier,et al.  Local recurrence after breast‐conserving surgery and radiotherapy. Frequency, time course, and prognosis , 1989, Cancer.

[36]  S. Schnitt,et al.  Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. , 1988, International journal of radiation oncology, biology, physics.

[37]  J. Boice.  Cancer following medical irradiation , 1981, Cancer.

[38]  L. Bégin,et al.  Germ-Line BRCA 1 Mutation Is an Adverse Prognostic Factor in Ashkenazi Jewish Women with Breast Cancer 1 , 2005 .

[39]  B. Agnarsson,et al.  Inherited BRCA2 mutation associated with high grade breast cancer , 2004, Breast Cancer Research and Treatment.

[40]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[41]  C. Bressac,et al.  The prognostic significance of late local recurrence after breast-conserving therapy. , 1990, International journal of radiation oncology, biology, physics.

[42]  A. Recht,et al.  Time course and prognosis of local recurrence following primary radiation therapy for early breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.